Clinical trials: Patients With Type 2 Diabetes
Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with…
- Trial name
- NCT02762370
- Testing
- FX006 32 mg, TCA IR 40 mg
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Diabetes Mellitus, Non-Insulin-Dependent
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug…
- Trial name
- NCT01105429
- Testing
- BMS-820132
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Type2 Diabetes
Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar).
- Trial name
- NCT05094401
- Testing
- BT-001
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Better Therapeutics
Diabetes, Diabetes Mellitus, Type 1
Observational Study on Levemir® in Obese Diabetic Patients
This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- KILOS (NCT00849342)
- Testing
- insulin detemir
- Where
- 2 sites in Netherlands, Slovenia
- Volunteers
- 580 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
- Trial name
- NCT02367131
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 419 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral…
- Trial name
- NCT00242372
- Testing
- Tesaglitazar 0.5, Insulin at least 30 units/day
- Where
- 71 sites in United States
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.
- Trial name
- NCT01605773
- Testing
- repaglinide, glyburide
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.
- Trial name
- NCT06649773
- Testing
- Noiiglutide Injection
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients…
- Trial name
- NCT01087502
- Testing
- Glimepiride, Linagliptin
- Where
- 52 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
The purpose of the study is to evaluate the efficacy, tolerability and short-term safety of LIK066 to support dose selection for phase 3.
- Trial name
- NCT01824264
- Testing
- LIK066, Sitagliptin
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Drug to Drug Interaction Study With ASP1941 and Metformin
A study to investigate the effect on safety, pharmacokinetics and pharmacodynamics when ASP1941 is administered as add-on therapy to metformin.
- Trial name
- NCT01302145
- Testing
- ASP1941, Metformin
- Where
- 5 sites in Hungary, Netherlands and 2 more
- Volunteers
- 36 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with…
- Trial name
- NCT07156500
- Testing
- HS-20094 Injection
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes
Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients
This is a multicentre, non-interventional, prospective, observational study which would be conducted in India to understand the usage and effect of saxagliptin as first add-on therapy after metformin.
- Trial name
- ONTARGET-INDIA (NCT02588859)
- Where
- 31 sites in India
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Comparison of Insulin Mix25 Versus Mix50
The purpose of this study is to determine the efficacy and safety of insulin Lispro Mix25 (LM25) compared to insulin Lispro Mix50 (LM50) as an insulin starter in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- CLASSIFY (NCT01773473)
- Testing
- Insulin Lispro Mix25, Insulin Lispro Mix50
- Where
- 27 sites in China, Japan and 2 more
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.
This 4 arm study will evaluate the tolerability, efficacy and pharmacodynamics of different doses of a GLP-1 analogue in patients with type 2 diabetes who are treated with a stable dose of metformin.
- Trial name
- NCT00460941
- Testing
- Taspoglutide 20mg, Taspoglutide 20mg-30mg, Taspoglutide 20mg-40mg
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 133 people
- Sponsor
- Hoffmann-La Roche
T2DM, Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT05680129
- Testing
- Ecnoglutide high dosage, Ecnoglutide low dosage, Dulaglutide
- Where
- China
- Volunteers
- 623 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Diabetes type2, Obesity
The RESET System Pivotal Clinical Trial (Protocol Revision K)
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.
- Trial name
- STEP-1 (NCT04101669)
- Testing
- RESET Liner
- Where
- 27 sites in United States
- Volunteers
- 264 people
- Sponsor
- Morphic Medical Inc.
Diabetes Mellitus, Type 2
Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
Primary objective: To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients Secondary objectives: To assess the forced titration on physician and patient satisfaction To evaluate…
- Trial name
- LANTIT (NCT00701831)
- Testing
- Insulin glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta®), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-X (NCT00707031)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 639 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants
This study is conducted in the United States of America. The aim of this study is to estimate incidence rates of all malignant neoplasms, specific subgroups of malignant neoplasms, and acute pancreatitis among cohorts of…
- Trial name
- NCT02608853
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 9,999 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.